On March 21, 2023 Fusion Antibodies plc (AIM: FAB), a contract research organisation ("CRO") providing discovery, design, and optimisation services for therapeutic antibodies to the global healthcare market, reported that it has filed a patent application for a panel of antibodies that bind to an important target for cancer therapeutics (Press release, Fusion Antibodies, MAR 21, 2023, View Source [SID1234629113]). These antibodies have the potential to inhibit the pro-tumourigenic activity of their target in cancer, which is supported by pre-clinical data. The Company is exploring options to out-licence these antibodies to a clinical development company to progress them into Phase I clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Adrian Kinkaid, CEO of Fusion, commented: "We have a dedicated team of scientists who continue to work on antibody discovery and expression, and we remain confident in our ability to grow and create opportunities in this field. We look forward to being able to update the market further, whilst also growing our patent portfolio."

Enquiries:

Fusion Antibodies plc www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
James Fair, Chief Financial Officer Via Walbrook PR

Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Vivek Bhardwaj (Corporate Finance)
Tony Quirke (Sales and Corporate Broking)

Walbrook PR Tel: +44 (0)20 7933 8780 or [email protected]
Anna Dunphy Mob: +44 (0)7876 741 001